Stayble Therapeutics AB (STABL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Stayble Therapeutics AB (STABL) has a cash flow conversion efficiency ratio of -0.194x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.34 Million ≈ $-144.31K USD) by net assets (Skr6.92 Million ≈ $744.92K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Stayble Therapeutics AB (STABL) balance sheet quality index to measure how much of total assets are equity-financed.
Stayble Therapeutics AB - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Stayble Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check STABL capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Stayble Therapeutics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Stayble Therapeutics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forward Water Technologies Corp
V:FWTC
|
-0.052x |
|
Springfield Properties Plc
LSE:SPR
|
-0.100x |
|
Ausmon Resources Ltd
AU:AOA
|
-0.232x |
|
Sky Gold Corp
V:SKYG
|
-0.256x |
|
Polledo S.A.
BA:POLL
|
0.130x |
|
SpectraCure AB
ST:SPEC
|
-0.048x |
|
Erech Finance Cahalacha Ltd
TA:EFNC
|
-0.213x |
|
Rainbow Polikarbonat Sanayi Ticaret AS
IS:RNPOL
|
0.103x |
Annual Cash Flow Conversion Efficiency for Stayble Therapeutics AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Stayble Therapeutics AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Stayble Therapeutics AB market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr6.92 Million ≈ $744.92K |
Skr-6.72 Million ≈ $-723.29K |
-0.971x | +54.50% |
| 2024-12-31 | Skr6.87 Million ≈ $739.64K |
Skr-14.67 Million ≈ $-1.58 Million |
-2.134x | -49.66% |
| 2023-12-31 | Skr16.51 Million ≈ $1.78 Million |
Skr-23.54 Million ≈ $-2.53 Million |
-1.426x | +12.45% |
| 2022-12-31 | Skr15.28 Million ≈ $1.64 Million |
Skr-24.89 Million ≈ $-2.68 Million |
-1.628x | -572.99% |
| 2021-12-31 | Skr39.81 Million ≈ $4.28 Million |
Skr-9.63 Million ≈ $-1.04 Million |
-0.242x | +84.31% |
| 2020-12-31 | Skr15.55 Million ≈ $1.67 Million |
Skr-23.98 Million ≈ $-2.58 Million |
-1.542x | -57.46% |
| 2019-12-31 | Skr-295.44K ≈ $-31.79K |
Skr289.39K ≈ $31.14K |
-0.980x | -28.49% |
| 2018-12-31 | Skr7.11 Million ≈ $765.43K |
Skr-5.42 Million ≈ $-583.53K |
-0.762x | -140.22% |
| 2017-12-31 | Skr8.25 Million ≈ $887.43K |
Skr-2.62 Million ≈ $-281.63K |
-0.317x | -152.05% |
| 2016-12-31 | Skr11.06 Million ≈ $1.19 Million |
Skr-1.39 Million ≈ $-149.87K |
-0.126x | -- |
About Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.